Enovis Corporation (NYSE:ENOV) Given Average Recommendation of “Moderate Buy” by Analysts

Enovis Corporation (NYSE:ENOV) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $40.3750.

Several equities analysts recently issued reports on ENOV shares. BTIG Research cut their price objective on shares of Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, September 1st. Citigroup restated a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. UBS Group reiterated a “buy” rating and issued a $51.00 price target (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Finally, Wells Fargo & Company reduced their price target on Enovis from $39.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, September 2nd.

Insider Activity

In related news, CEO Damien Mcdonald bought 13,035 shares of the business’s stock in a transaction on Friday, September 4th. The shares were bought at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the purchase, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Oliver Engert purchased 5,140 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were purchased at an average cost of $19.46 per share, with a total value of $100,024.40. Following the completion of the transaction, the insider owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. The trade was a 9.16% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 24,293 shares of company stock worth $470,519 in the last quarter. 2.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Enovis

Institutional investors have recently bought and sold shares of the company. IFP Advisors Inc increased its position in shares of Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after purchasing an additional 1,174 shares in the last quarter. Arax Advisory Partners acquired a new stake in shares of Enovis in the 4th quarter worth $29,000. Allworth Financial LP purchased a new position in Enovis during the 2nd quarter worth $36,000. Integrated Wealth Concepts LLC purchased a new position in Enovis during the 2nd quarter worth $39,000. Finally, EverSource Wealth Advisors LLC increased its position in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Up 6.2%

Shares of Enovis stock opened at $19.54 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -1.01 and a beta of 1.31. The firm’s 50-day moving average is $25.25 and its two-hundred day moving average is $24.10. Enovis has a 1 year low of $18.08 and a 1 year high of $34.28.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same quarter in the previous year, the business posted $0.79 EPS. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts expect that Enovis will post 3.15 earnings per share for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.